Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bert Vander Cruyssen

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Annals of the Rheumatic Diseases|January 25, 2018
Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritisLieve Van Hoovels, Julie Jacobs, Bert Vander Cruyssen, et al.
Annals of the Rheumatic Diseases|July 15, 2006
Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitopeBert Vander Cruyssen, Ilse E A Hoffman, Isabelle Peene, et al.
The EMBO Journal|May 31, 2008
Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-kappaB inhibitionIlse M E Beck, Wim Vanden Berghe, Linda Vermeulen, et al.
Plos One|November 13, 2010
Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitisDebby Laukens, Michel Georges, Cécile Libioulle, et al.
Journal of Gastroenterology and Hepatology|August 30, 2007
Clinical and genetic factors associated with sacroiliitis in Crohn's diseaseHarald Peeters, Bert Vander Cruyssen, Herman Mielants, et al.
Reumatologia Clinica|March 7, 2014
ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapyNathan Vastesaeger, Bert Vander Cruyssen, Juan Mulero, et al.
Rheumatology (Oxford, England)|February 25, 2011
Optimized alkylated cyclodextrin polysulphates with reduced risks on thromboembolic accidents improve osteoarthritic chondrocyte metabolismSara Groeneboer, Stijn Lambrecht, Aad Dhollander, et al.
Rheumatology (Oxford, England)|July 17, 2009
Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgeryBert Vander Cruyssen, Elisa Muñoz-Gomariz, Pilar Font, et al.
The Journal of Rheumatology|May 19, 2009
Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcomeAnnelies Boonen, Bert vander Cruyssen, Kurt de Vlam, et al.
Annals of the Rheumatic Diseases|January 31, 2007
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practiceBert Vander Cruyssen, Clio Ribbens, Annelies Boonen, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Annals of the Rheumatic Diseases|January 25, 2018
Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritisLieve Van Hoovels, Julie Jacobs, Bert Vander Cruyssen, et al.
Annals of the Rheumatic Diseases|July 15, 2006
Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitopeBert Vander Cruyssen, Ilse E A Hoffman, Isabelle Peene, et al.
The EMBO Journal|May 31, 2008
Altered subcellular distribution of MSK1 induced by glucocorticoids contributes to NF-kappaB inhibitionIlse M E Beck, Wim Vanden Berghe, Linda Vermeulen, et al.
Plos One|November 13, 2010
Evidence for significant overlap between common risk variants for Crohn's disease and ankylosing spondylitisDebby Laukens, Michel Georges, Cécile Libioulle, et al.
Journal of Gastroenterology and Hepatology|August 30, 2007
Clinical and genetic factors associated with sacroiliitis in Crohn's diseaseHarald Peeters, Bert Vander Cruyssen, Herman Mielants, et al.
Reumatologia Clinica|March 7, 2014
ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapyNathan Vastesaeger, Bert Vander Cruyssen, Juan Mulero, et al.
Rheumatology (Oxford, England)|February 25, 2011
Optimized alkylated cyclodextrin polysulphates with reduced risks on thromboembolic accidents improve osteoarthritic chondrocyte metabolismSara Groeneboer, Stijn Lambrecht, Aad Dhollander, et al.
Rheumatology (Oxford, England)|July 17, 2009
Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgeryBert Vander Cruyssen, Elisa Muñoz-Gomariz, Pilar Font, et al.
The Journal of Rheumatology|May 19, 2009
Spinal radiographic changes in ankylosing spondylitis: association with clinical characteristics and functional outcomeAnnelies Boonen, Bert vander Cruyssen, Kurt de Vlam, et al.
Annals of the Rheumatic Diseases|January 31, 2007
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practiceBert Vander Cruyssen, Clio Ribbens, Annelies Boonen, et al.
Pageof 4